Skip to main content
. 2018 May 10;31(5):572–582. doi: 10.20524/aog.2018.0276

Table 4.

Quality of evidence for clinically relevant outcomes. Tofacitinib compared to placebo for moderate-to-severe ulcerative colitis

graphic file with name AnnGastroenterol-31-572-g005.jpg